Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2022401 | 0.89 | RET (0.34) | RETPTGDR2DRD2HTR6 | |
| SCHEMBL2026412 | 0.89 | RET (0.34) | RETPTGDR2DRD2HTR6 | |
| SCHEMBL13626057 | 0.89 | CYP2C19 (0.32) | RETPTGDR2DRD2 | |
| SCHEMBL12640885 | 0.85 | PTGDR2 (0.30) | PTGDR2DRD2 | |
| SCHEMBL14218047 | 0.80 | PTGDR2 (0.32) | PTGDR2 | |
| SCHEMBL16493840 | 0.80 | SCARB1 (0.35) | RETPTGDR2DRD2HTR6 | |
| SCHEMBL13563275 | 0.80 | PTGDR2 (0.37) | PTGDR2 | |
| SCHEMBL2024062 | 0.79 | RORC (0.35) | RETPTGDR2DRD2HTR6 | |
| SCHEMBL2024064 | 0.79 | RORC (0.35) | RETPTGDR2DRD2HTR6 | |
| SCHEMBL2023482 | 0.78 | HRH1 (0.35) | RETPTGDR2DRD2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968587-B2 | Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100069404-A1 | TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2010-03-18 | — | — | US | disclosed |
| WO-2008063867-A2 | TETRAHYDROCYCLOPENTA[B] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069404-A1 | TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, NR5A1, MUSK | RET 2310/4885PTGDR2 238/4885DRD2 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.